Our work addresses the role of PARP-1 as a target for chemotherapeutic intervention in both MSI and MSS CRC by applying novel PARP inhibitors to overcome PARPi resistance and reduce cytotoxicity-mediated adverse effects. The gene discussed is PARP1; the disease is colorectal carcinoma.